The combination of immune checkpoint blockade with chemotherapy is currently under investigation as a promising strategy for the treatment of triple negative breast cancer (TNBC). Tumor-associated macrophages (TAMs) are the most prominent component of the breast cancer microenvironment because they influence tumor progression and the response to therapies. Here we show that macrophages acquire an immunosuppressive phenotype and increase the expression of programmed death ligand-1 (PD-L1) when treated with reactive oxygen species (ROS) inducers such as the glutathione synthesis inhibitor, buthionine sulphoximine (BSO), and paclitaxel. Mechanistically, these agents cause accumulation of ROS that in turn activate NF-κB signaling to promote PD-L1 transcription and the release of immunosuppressive chemokines. Systemic in vivo administration of paclitaxel promotes PD-L1 accumulation on the surface of TAMS in a mouse model of TNBC, consistent with in vitro results. Combinatorial treatment with paclitaxel and an anti-mouse PD-L1 blocking antibody significantly improved the therapeutic efficacy of paclitaxel by reducing tumor burden and increasing the number of tumor-associated cytotoxic T cells. Our results provide a strong rationale for the use of anti–PD-L1 blockade in the treatment of TNBC patients. Furthermore, interrogation of chemotherapy-induced PD-L1 expression in TAMs is warranted to define appropriate patient selection in the use of PD-L1 blockade.

Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1

Roux, Cecilia;Cappello, Paola
Co-last
;
2019-01-01

Abstract

The combination of immune checkpoint blockade with chemotherapy is currently under investigation as a promising strategy for the treatment of triple negative breast cancer (TNBC). Tumor-associated macrophages (TAMs) are the most prominent component of the breast cancer microenvironment because they influence tumor progression and the response to therapies. Here we show that macrophages acquire an immunosuppressive phenotype and increase the expression of programmed death ligand-1 (PD-L1) when treated with reactive oxygen species (ROS) inducers such as the glutathione synthesis inhibitor, buthionine sulphoximine (BSO), and paclitaxel. Mechanistically, these agents cause accumulation of ROS that in turn activate NF-κB signaling to promote PD-L1 transcription and the release of immunosuppressive chemokines. Systemic in vivo administration of paclitaxel promotes PD-L1 accumulation on the surface of TAMS in a mouse model of TNBC, consistent with in vitro results. Combinatorial treatment with paclitaxel and an anti-mouse PD-L1 blocking antibody significantly improved the therapeutic efficacy of paclitaxel by reducing tumor burden and increasing the number of tumor-associated cytotoxic T cells. Our results provide a strong rationale for the use of anti–PD-L1 blockade in the treatment of TNBC patients. Furthermore, interrogation of chemotherapy-induced PD-L1 expression in TAMs is warranted to define appropriate patient selection in the use of PD-L1 blockade.
2019
116
10
4326
4335
https://www.pnas.org/content/pnas/116/10/4326.full.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410837/
Chemotherapy; Immune suppression; Macrophages; Programmed death ligand-1; Reactive oxygen species;
Roux, Cecilia; Jafari, Soode Moghadas; Shinde, Rahul; Duncan, Gordon; Cescon, David W.; Silvester, Jennifer; Chu, Mandy F.; Hodgson, Kelsey; Berger, Thorsten; Wakeham, Andrew; Palomero, Luis; Garcia-Valero, Mar; Pujana, Miguel A.; Mak, Tak W.*; McGaha, Tracy L.; Cappello, Paola; Gorrini, Chiara
File in questo prodotto:
File Dimensione Formato  
Roux_PNAS_postprint.pdf

Accesso aperto

Descrizione: Accepted manuscript
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 2.08 MB
Formato Adobe PDF
2.08 MB Adobe PDF Visualizza/Apri
Roux et al_PNAS 2019 .pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.99 MB
Formato Adobe PDF
1.99 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1696701
Citazioni
  • ???jsp.display-item.citation.pmc??? 79
  • Scopus 136
  • ???jsp.display-item.citation.isi??? 117
social impact